Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

8-ukers flerstedsstudie av MYDAYIS® for bipolar depresjon

22. oktober 2026 oppdatert av: Mark Frye, Mayo Clinic

An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS® (D-amphetamine / L-amphetamine) for Bipolar Depression

This protocol is a Phase 2 multi-site study which aims to evaluate the safety and effectiveness of MYDAYIS® as adjunctive therapy for adults with bipolar depression. Results from this study WILL NOT be used to contribute to an approval of MYDAYIS ® for this indication.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

77

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Mayo Clinic in Rochester
    • Ohio
      • Mason, Ohio, Forente stater, 45040
        • Lindner Center of Hope

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria

  1. Male or female between 18 and 65 years of age
  2. Bipolar I or II disorder as confirmed by structured diagnostic clinical interview for DSM-IV-TR.
  3. Subsyndromal depressive symptoms or major depressive episode unresponsive to steady and stable (ie, at least 2 weeks) mood stabilization (eg, lithium, valproate, lamotrigine, carbamazepine/oxcarbamazepine, and/or atypical antipsychotic therapy) and non-psychotropic medication.
  4. Antidepressant therapy is allowed in the study as long as patients are also on a mood stabilizer. Patients will be enrolled provided that any needed modifications to the antidepressant would be made at least two weeks prior to randomization.
  5. Patients receiving psychotherapy will be allowed to be randomized provided therapy frequency does not change during the 8-week blinded phase.
  6. Symptom severity score on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) ≥9, and the Clinical Global Impression for Bipolar Illness (CGI-BP) Depression Severity Scale ≥ 3.
  7. Patients on stimulants for comorbid attention deficit disorder (ADHD) and/or binge eating disorder (BED) will be enrolled provided that the stimulant can be tapered and discontinued at least one week prior to randomization; symptom severity inclusion criteria 4.1.3 or presence of subsyndromal symptoms must be met again prior to randomization.
  8. Patients with a prescribed opiate (eg. hydroxicodone) or other pain intervention for acute or chronic pain management will be allowed provided they: 1) use of a prescribed opiate or other pain intervention at a recommendation dose and established duration; 2) show no evidence of prescription misuse; 3) do not meet abuse or dependence criteria by SCID; 4) no known significant pharmacological interactions.
  9. Ability to travel for the assessment visits.

Exclusion Criteria

  1. Inability to provide written informed consent.

  2. Inability to understand English.

  3. Score less than 86% correct (ie, one wrong) on comprehension assessment that reviews study goals.

  4. Clinically significant signs of acute suicidality from any of the following assessments:

    1. Response of > 2 on question #12 of QIDS-C or
    2. Response = 3 on the SCID Module A- #A19
  5. Medically serious suicide attempt within the past 6 months (medically serious defined as an ED evaluation and procedure and/or admit to inpatient unit such as internal medicine, cardiac, or ICU).

  6. Concomitant treatment with monoamine oxidase inhibitors (MAOIs); also, within 14 days following discontinuation of treatment with a monoamine oxidase inhibitor.

  7. Baseline Young Mania Rating Scale (YMRS) score ≥ 12.

  8. Patients with active psychosis (measured by a score >4 on YMRS question #8) or a diagnosis of schizophrenia, schizoaffective disorder, delusional, or schizophreniform disorder identified by structured clinical interview for DSM-IV-TR.

  9. Active abuse or dependence of alcohol, opiates, or cannabis (nicotine dependence will be an exception) by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 3 months can be randomized.

  10. Positive toxicology screen for drugs of abuse (ie, cocaine, methamphetamine, illegal opiates).

  11. Positive toxicology screen for cannabis and a cannabis use disorder by structured clinical interview for DSM-IV-TR. Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less

  12. Known lifetime history of cocaine or methamphetamine abuse or dependence identified by structured clinical interview for DSM-IV-TR.

  13. Active stimulant prescription abuse or dependence by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 6 months can be randomized.

  14. Known lifetime history of stimulant-induced mania.

  15. Known hypersensitivity, such as angioedema or anaphylaxis, to amphetamines or other ingredients of MYDAYIS.

  16. Clinically unstable medical disease.

  17. Known history of a structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormality, coronary artery disease, stroke, or other serious cardiovascular problems.

  18. ECG with clinically significant arrhythmias, conduction abnormalities, or voltage criteria met for left ventricular hypertrophy (unless cleared by cardiology consultation).

  19. Uncontrolled hypertension (>160/100) or tachycardia (heart rate >110).

  20. History of grand mal seizure; history of febrile seizure as infant permitted.

  21. Established vasculopathy or history of Raynaud's phenomena.

  22. Narrow angle glaucoma.

  23. Chronic kidney disease (CKD) > stage IIIa (GFR 40-59).

  24. Tourette syndrome.

  25. Women who are pregnant, lactating or of child-bearing potential not using at least one adequate contraceptive measure (ie, hormonal contraception-birth control pills, intrauterine devices (IUD), tubal ligation or condoms during sexual intercourse).

  26. Current positive test for SARS-CoV-2; those with previous COVID-19 illness and those who test positive for SARS-CoV-2 any time after starting study drug or placebo will be included.

  27. Otherwise excluded for administrative reasons and/or clinician judgment.

  28. Daily use of lorazepam (Ativan) at doses > 2 mg per day (or dose equivalent: clonazepam (Klonopin) > 1 mg, alprazolam (Xanax) > 1-2 mg, or diazepam (Valium) >20 mg) [58].

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Mydayis - Active

MYDAYIS®, Oral administration, dose regimen for Double blind phase and open label phase.

12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days

Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®

Andre navn:
  • d-amfetamin / l-amfetamin
Placebo komparator: Placebo

Matching placebo, Oral administration, dose regimen for Double blind phase and open label phase.

12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days

Matching placebo

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score
Tidsramme: Baseline to week 8

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean percent reduction from baseline in participants' total MADRS score, with greater percent reductions indicating greater improvement in depressive symptoms.

Baseline to week 8
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score-Open Label Extension
Tidsramme: Week 8 to Week 16

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean absolute change from week 8 to week 16 in participants' total MADRS score. Negative values indicate a reduction in depressive symptom severity.

Week 8 to Week 16

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Quick Inventory for Depressive Symptomatology (QIDS-C-16 and QIDS-SR-16) Score
Tidsramme: Baseline to Week 8

The QIDS-C-16 (Quick Inventory of Depressive Symptomatology - Clinician) and QIDS-SR-16 (Quick Inventory of Depressive Symptomatology - Self Report) are 16-item questionnaires designed to assess the severity of depressive symptoms. They are widely used by healthcare providers to monitor treatment progress and symptom changes over time. They are scored the same. Scores are calculated by summing the responses to nine core symptom domains. The total score ranges from 0 to 27, with higher scores indicating greater depression severity. The outcome measure was mean percent reduction from baseline in total QIDS-C-16 and QIDS-SR-16 scores, with greater reductions indicating greater improvement in depressive symptoms.

Baseline to Week 8
Remission
Tidsramme: Baseline to Week 8

The number of subjects who had treatment remission defined as having a Montgomery-Asberg Depression Rating Scale (MADRS) score < 10. (Score Range 0-60)

Baseline to Week 8
Change in General Anxiety Disorder 7-item (GAD-7) Scale Score
Tidsramme: Baseline to Week 8 visit 10

The GAD-7 scale is used to assess anxiety symptoms in individuals. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.

Baseline to Week 8 visit 10
Response
Tidsramme: Baseline to Week 8 visit 10

The number of subjects who had a treatment response defined as a 50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score (Range: 0-60).

Baseline to Week 8 visit 10
Improvement of Clinical Global Impression for Bipolar Disorder (CGI-I) Score
Tidsramme: Baseline to Week 8 visit 10

The number of subjects who had improvement in their CGI-I score. This scale evaluates how much the patient's illness has improved or worsened relative to their baseline state (prior to starting treatment). Scores range from 1-7 with lower scores indicating higher improvement.

Baseline to Week 8 visit 10
Change in Young Mania Rating Scale (YMRS) Score
Tidsramme: Baseline to Week 8

The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean percent change from baseline in the total YMRS score. A greater decrease from baseline (more negative percent change) indicates improvement in manic symptoms.

Baseline to Week 8
Change in Young Mania Rating Scale (YMRS) Score-Open Label Extension
Tidsramme: Week 8 to Week 16

The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean change from week 8 to week 16 in the total YMRS score.

Week 8 to Week 16
Change in Epworth Sleepiness Scale (ESS) Score
Tidsramme: Baseline to Week 8

The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire that measures the average level of daytime sleepiness. By rating the likelihood of dozing off in 8 daily scenarios, a total score ranging from 0 to 24 is calculated. A higher score indicates greater daytime sleepiness and increased severity of sleepiness symptoms. The outcome measure was the mean percent change from baseline in the total ESS score. A greater decrease from baseline (more negative percent change) indicates improvement in daytime sleepiness.

Baseline to Week 8
Change in Fatigue Severity Scale (FSS) Score
Tidsramme: Baseline to Week 8

The Fatigue Severity Scale (FSS) evaluates how fatigue impacts daily life. It contains 9 statements, each rated on a 1-to-7 scale (1 = strongly disagree, 7 = strongly agree). Total scores range from 9 to 63 with higher scores indicating worse fatigue. The outcome measure was the mean percent change from baseline in the total FSS score. A greater decrease from baseline (more negative percent change) indicates improvement in fatigue severity.

Baseline to Week 8
Change in Binge Eating Scale (BES) Score
Tidsramme: Baseline to Week 8

The Binge Eating Scale (BES) is a self-reported questionnaire designed to assess the presence and severity of binge eating behaviors and characteristics associated with binge eating. Total scores range from 0 to 48 with higher scores indicating greater severity of binge eating symptoms.

Baseline to Week 8
Change in Rapid Eating and Activity Assessment for Patients (REAP) Score
Tidsramme: Baseline to Week 8

The Rapid Eating and Activity Assessment for Patients (REAP) is a self-reported questionnaire used to assess dietary habits and physical activity behaviors. Total REAP scores range from 0 to 27 with higher scores indicating healthier nutrition and physical activity behaviors. The outcome measure was the mean percent change from baseline in the total REAP score. A greater increase from baseline indicates improvement in dietary and physical activity behaviors.

Baseline to Week 8
Change in Digit Symbol Substitution Test (DSST) Score
Tidsramme: Baseline to Week 8

The Digit Symbol Substitution Test (DSST) is a neuropsychological assessment of cognitive performance that measures processing speed, working memory, and visuomotor coordination. Participants are required to match symbols to corresponding number according to a provided key within a fixed time period of 90 seconds. The raw score is simply the total number of correctly matched symbols completed within the time limit (90 seconds). Scores range from 0 to the total number of correct responses achieved, with higher scores indicating better cognitive performance. The outcome measure was the mean percent change from baseline in DSST score. A greater increase from baseline indicates improvement in cognitive performance.

Baseline to Week 8
Morningness-Eveningness Questionnaire (MEQ) Score
Tidsramme: Baseline

The Morningness-Eveningness Questionnaire (MEQ) is a self-assessment tool used to determine a person's preferred timing for sleep and peak alertness during the day. Total scores range from 16 to 86 with higher scores indicating a stronger morning preference, whereas lower scores indicate a stronger evening preference.

Baseline

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Mark A Frye, Mayo Clinic

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. november 2020

Primær fullføring (Faktiske)

25. juli 2025

Studiet fullført (Faktiske)

25. juli 2025

Datoer for studieregistrering

Først innsendt

4. desember 2019

Først innsendt som oppfylte QC-kriteriene

16. januar 2020

Først lagt ut (Faktiske)

22. januar 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

22. oktober 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere